Venture roundup: ImmusanT, Locus

On Nov. 14, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million.

ImmusanT raised $40 million in a series C round led by new investor Arch Venture Partners, with participation from existing investor Vatera Healthcare Partners. Arch's Steven Gillis and Thomas Daniel will join ImmusanT's board...